Market Price

102.99 

0.84 0.8%

as of Mar 05 '21

52 Week Range:

16.87 127.11


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Natera, Inc. provides preconception and prenatal genetic testing services. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora products of conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; and Signatera, a circulating tumor DNA technology that analyzes and tracks mutations to an individual's tumor. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners in the United States and internationally. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Equity (BVPS) 4.09
2.66
0.56
0.91
1.09
growth rate -35.0% -79.0% 62.5% 19.8%
Earnings BIT 0.67
-58.84
-98.95
-135.34
-114.63
-116.29
-216.28
growth rate -100.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Avg.PE -4.27
-4.59
-4.59
-4.59
-4.59
growth rate 0.0% 0.0% 0.0% 0.0%
ROA -62.14
-5.62
-36.14
-40.24
-70.00
-57.35
-29.34
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ROE -65.76
-283.67
-80.31
growth rate 0.0% 0.0%
ROIC -234.13
-50.28
-79.08
-89.77
-40.12
growth rate 0.0% 0.0% 0.0% 0.0%
Cur. Ratio 2.08
3.56
3.12
1.81
1.37
2.11
2.91
growth rate 71.2% -12.4% -42.0% -24.3% 54.0% 37.9%
Quick Ratio 1.58
3.12
2.94
1.65
1.20
1.90
2.75
growth rate 97.5% -5.8% -43.9% -27.3% 58.3% 44.7%
Leverage 1.44
1.98
8.34
2.09
growth rate 37.5% 105.2% -74.9%
Balance Sheet Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Acct.Receivable 6.63
5.94
5.86
13.40
44.09
62.22
53.35
78.57
growth rate -10.4% -1.4% 128.5% 229.1% 41.1% -14.3% 47.3%
Acct.Payable 20.19
8.87
15.07
12.02
9.90
17.33
12.91
growth rate -56.1% 69.9% -20.2% -17.7% 75.1% -25.5%
Cur.Assets 49.11
106.48
250.73
174.12
180.63
240.52
523.17
862.66
growth rate 116.8% 135.5% -30.6% 3.7% 33.2% 117.5% 64.9%
Total Assets 59.72
123.62
265.24
210.68
214.61
268.17
582.66
932.15
growth rate 107.0% 114.6% -20.6% 1.9% 25.0% 117.3% 60.0%
Cash 30.65
87.18
28.95
15.26
12.62
46.41
61.93
48.67
growth rate 184.5% -66.8% -47.3% -17.3% 267.7% 33.4% -21.4%
Inventory 10.65
11.54
8.09
6.41
9.00
13.63
12.39
20.03
growth rate 8.4% -29.9% -20.8% 40.3% 51.5% -9.1% 61.6%
Cur.Liabilities 23.57
29.87
80.48
96.42
105.56
113.98
179.87
199.05
growth rate 26.7% 169.4% 19.8% 9.5% 8.0% 57.8% 10.7%
Liabilities 46.03
54.35
80.48
104.20
189.20
236.01
303.95
445.92
growth rate 18.1% 48.1% 29.5% 81.6% 24.7% 28.8% 46.7%
LT Debt 1.38
24.47
73.07
73.36
73.66
202.49
growth rate 1,670.9% 44.0% 0.4% 0.4% 174.9%
Equity -171.34
184.77
106.48
25.42
32.16
278.71
486.24
growth rate 100.0% -42.4% -76.1% 26.5% 766.6% 74.5%
Common Shares 37.00
37.00
26.00
52.00
54.00
62.08
78.01
86.22
growth rate 0.0% -29.7% 100.0% 3.9% 15.0% 25.7% 10.5%
Cash Flow Statement Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Capital Expenditures 8.25
9.96
7.85
23.14
9.87
3.88
4.97
19.60
growth rate 20.8% -21.1% 194.7% -57.4% -60.7% 28.0% 294.6%
Cash From OA 10.49
-37.83
-74.05
-97.83
-70.58
-63.44
-182.51
growth rate -100.0% 0.0% 0.0% 0.0% 0.0% 0.0%
FCF per Share -0.67
-1.28
-2.19
-1.56
-1.00
growth rate 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock 33.26
0.17
181.45
6.18
5.66
growth rate -99.5% 106,635.9% -96.6% -8.5%
FCF -32.00
1.00
-46.00
-97.00
-107.00
-74.00
-68.00
-202.12
growth rate 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Income Statement Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Sales 55.17
159.29
190.36
212.51
209.63
247.19
306.02
370.08
growth rate 188.7% 19.5% 11.6% -1.4% 17.9% 23.8% 20.9%
Op.Income -37.11
0.67
-58.84
-98.95
-135.34
-114.63
-116.29
-216.28
growth rate 100.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0%
IBT -37.11
-5.15
-70.28
-100.19
-137.17
-127.85
-122.83
-229.65
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Net Income -37.11
-5.15
-70.28
-100.33
-137.63
-128.15
-124.83
-229.74
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
EPS -1.01
-0.14
-2.68
-1.95
-2.59
-2.22
-1.79
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Gross Profit 17.90
80.89
78.51
78.84
70.03
246.89
305.72
369.88
growth rate 352.0% -3.0% 0.4% -11.2% 252.6% 23.8% 21.0%
R&D 11.55
17.29
27.71
41.86
50.06
-51.36
-51.36
-100.04
growth rate 49.7% 60.3% 51.1% 19.6% -100.0% 0.0% 0.0%

Quarterly Statements

Item Name Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Earnings BIT -34.81
-34.87
-51.66
-55.78
-73.97
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Acct.Receivable 53.35
61.58
58.71
70.67
growth rate 15.4% -4.7% 20.4%
Acct.Payable 12.91
16.19
9.27
17.87
growth rate 25.5% -42.7% 92.7%
Cur.Assets 523.17
497.21
663.50
916.01
862.66
growth rate -5.0% 33.5% 38.1% -5.8%
Total Assets 582.66
558.64
723.26
976.71
932.15
growth rate -4.1% 29.5% 35.0% -4.6%
Cash 61.93
74.14
77.32
209.35
growth rate 19.7% 4.3% 170.8%
Inventory 12.39
14.16
18.03
20.38
20.03
growth rate 14.3% 27.3% 13.0% -1.7%
Cur.Liabilities 179.87
176.64
175.56
195.87
199.05
growth rate -1.8% -0.6% 11.6% 1.6%
Liabilities 303.95
299.71
418.99
440.71
445.92
growth rate -1.4% 39.8% 5.2% 1.2%
LT Debt 73.66
72.88
197.48
199.96
growth rate -1.1% 171.0% 1.3%
Equity 278.71
258.93
304.27
536.00
486.24
growth rate -7.1% 17.5% 76.2% -9.3%
Common Shares 78.01
78.65
79.72
85.28
86.22
growth rate 0.8% 1.4% 7.0% 1.1%
Cash Flow Statement Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Capital Expenditures -0.14
7.92
2.21
1.94
7.53
growth rate 100.0% -72.1% -12.2% 287.6%
Cash From OA 96.87
-35.10
-40.98
-33.13
-73.30
growth rate -100.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock
growth rate
FCF 96.73
-43.02
-43.19
-35.07
-80.83
growth rate -100.0% 0.0% 0.0% 0.0%
Income Statement Dec '19 Mar '20 Jun '20 Sep '20 Dec '20
Sales 83.24
91.55
76.59
93.87
108.07
growth rate 10.0% -16.3% 22.6% 15.1%
Op.Income -34.81
-34.87
-51.66
-55.78
-73.97
growth rate 0.0% 0.0% 0.0% 0.0%
IBT -35.20
-35.35
-59.62
-58.30
-76.38
growth rate 0.0% 0.0% 0.0% 0.0%
Net Income -35.18
-35.37
-59.64
-58.32
-76.41
growth rate 0.0% 0.0% 0.0% 0.0%
Gross Profit 38.78
50.03
33.86
178.30
107.69
growth rate 29.0% -32.3% 426.7% -39.6%
R&D -15.00
-18.23
-23.01
-26.42
-32.38
growth rate 0.0% 0.0% 0.0% 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

E (19.95)

YOY Growth Grade:

F (8.89)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE -4.59 -36.26 -29.43
EPS / Growth 0.0% -2.84

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.0% 25.0% 50.0%
Future PE 0.00 0.01 33.34
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.